Structure-signal relationships of the δ-opioid-receptor (DOR)-selective agonist KNT-127 - Part I: Impact of the morphinan skeleton on the G-protein-biased DOR agonism

17 October 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The δ-opioid receptor (DOR) is a promising target for developing novel analgesics due to its lower risk of causing side effects compared to the μ-opioid receptor (MOR), which is commonly associated with dependence, respiratory depression, and other adverse effects. KNT-127, a DOR-selective agonist with a morphinan skeleton, offers analgesic and antidepressant benefits without inducing convulsions at therapeutic doses, unlike the conventional DOR agonist SNC80. While previous studies have suggested that KNT-127 exhibits reduced β-arrestin recruitment, a signaling pathway implicated in adverse opioid effects, the ligand structural basis for this biased signaling remains unclear. In this study, we explored the structure–signal relationships of KNT-127, focusing on its quinoline moiety. Modifying the quinoline moiety by removing the aromatic rings reduced DOR selectivity and potency in relation to G-protein activation while diminishing both the potency and efficacy of β-arrestin recruitment. These results suggest that the morphinan skeleton is critical for reduced β-arrestin recruitment, while the quinoline moiety differentially modulates G-protein activation and β-arrestin recruitment. Together, our study thus provides structural insights into the G-protein-biased agonism of DOR agonists, guiding the design of safer DOR-targeting therapeutics.

Keywords

δ-opioid receptor
μ-opioid receptor
κ-opioid receptor
G-protein-biased opioid agonist
β-arrestin

Supplementary materials

Title
Description
Actions
Title
Supplementary materials
Description
1H and 13C NMR spectra of the assayed compounds. Figure S1: Structural determination of KNT-127. Figure S2: Structural determination of 12. Figure S3: Concentration-response curves of Met-Enk, KNT-127, 1, and 2 against the opioid receptors.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.